Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.65 |
| ▸ | HTR1D | P28221 | 7/20 | 0.56 |
| ▸ | HTR1A | P08908 | 6/20 | 0.56 |
| ▸ | HTR2C | P28335 | 5/20 | 0.56 |
| ▸ | HTR1B | P28222 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | HTR6 | P50406 | 3/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | MPO | P05164 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.56 |
| ▸ | HTR3B | O95264 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022336 | 1.00 | HTR2A (0.65) | HTR2ATRPM8HTR1DHTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL7681061 | 0.98 | HTR2A (0.63) | HTR2ATRPM8HTR1DHTR1AHTR2C | |
| SCHEMBL25425428 | 0.88 | GPR84 (0.63) | HTR2ATRPM8HTR1DHTR1AHTR2C | |
| SCHEMBL2535076 | 0.88 | GPR84 (0.73) | HTR2ATRPM8HTR1DHTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL2538417 | 0.86 | GPR84 (0.61) | HTR2ATRPM8HTR1DHTR1AHTR2C | |
| SCHEMBL893023 | 0.86 | HTR2A (0.58) | HTR2ATRPM8HTR1DHTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL21546055 | 0.86 | GPR84 (0.71) | HTR2ATRPM8HTR1DHTR1AHTR2C | |
| SCHEMBL14907363 | 0.86 | HTR2C (0.62) | HTR2ATRPM8HTR1DHTR1AHTR2C | |
| SCHEMBL8808151 | 0.83 | GPR84 (0.51) | HTR2ATRPM8HTR1DHTR1AHTR2C | |
| SCHEMBL2540560 | 0.82 | CYP1A2 (0.63) | HTR2ATRPM8HTR1DHTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391926-A1 | SPIROINDOLINONE COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC | 2024-11-28 | — | — | US | disclosed |
| EP-4351569-A2 | SPIROINDOLINONE COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117597120-A | Spiroindolone compounds as Kv1.3 potassium Shaker channel blockers | D·E·萧尔研究有限责任公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20220403428-A1 | YEAST CELLS AND METHODS FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES | DANMARKS TEKNISKE UNIVERSITET (DK) | 2022-12-22 | — | — | US | disclosed |
| WO-2022251561-A2 | SPIROINDOLINONE COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022251561-A2 | SPIROINDOLINONE COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-4031671-A1 | YEAST CELLS AND METHODS FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES | Danmarks Tekniske Universitet (DK) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021052989-A1 | YEAST CELLS AND METHODS FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES | DANMARKS TEKNISKE UNIVERSITET (DK) | 2021-03-25 | — | — | WO | disclosed |
| EP-2651888-B1 | N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders | UNIV LEUVEN KATH (BE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2651887-B1 | N-(2-(5-substituted-1H-indol-3-yl)ethyl)biphenyl-4-carboxamide derivatives and related compounds as Tau-aggregation induced toxicity inhibitors for the treatment of neurodegenerative disorders | UNIV LEUVEN KATH (BE) | 2016-08-24 | — | — | EP | disclosed |
| US-9284271-B2 | Compounds for the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-03-15 | — | — | US | disclosed |
| US-9266832-B2 | Compounds for the treatment of neurodegenerative diseases | Katholieke Universiteit Levun (BE) | 2016-02-23 | — | — | US | disclosed |
| US-20130289033-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-31 | — | — | US | disclosed |
| EP-2651887-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651888-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-17 | — | — | US | disclosed |
| WO-2012080220-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080221-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-21 | — | — | WO | disclosed |
| EP-1070716-A1 | Beta-carboline derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, PSEN1 | HTR2A 1488/4885TRPM8 1909/4885HTR1D 801/4885 |
| US-20240391926-A1 | SPIROINDOLINONE COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNK3, KCNJ2, KCND3 | HTR2A 1749/4885TRPM8 92/4885HTR1D 764/4885 |
| US-20130289033-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, PSEN1 | HTR2A 1282/4885TRPM8 1867/4885HTR1D 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.